戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 y in models of amyotrophic lateral sclerosis-fused in sarcoma (ALS-FUS).
2 on to the dendrites is impaired by depleting fused in sarcoma-an amyotrophic lateral sclerosis-relate
3 au, a-synuclein, TAR DNA binding protein-43, fused in sarcoma and mutant huntingtin, all share low co
4 ald's rule also holds for the aggregation of fused in sarcoma and polyglutamine proteins.
5 ue TDP-43 (TAR DNA-binding protein 43), FUS (fused in sarcoma), and alpha-synuclein toxicity in yeast
6 ing FMRP in fragile X syndrome; TDP-43, FUS (fused in sarcoma), angiogenin, and ataxin-2 in amyotroph
7 TDP-43 (TAR DNA-binding protein 43) and FUS (fused in sarcoma) are aggregation-prone RNA-binding prot
8    Mutations in the RNA-binding protein FUS (fused in sarcoma) are linked to amyotrophic lateral scle
9                    Using RNA-binding protein fused-in-sarcoma as a model for condensates implicated i
10 ces as well as an archetypal disordered RNP, fused in sarcoma, as model systems, we investigate the m
11 sordered prion-like low-complexity domain of Fused in Sarcoma by performing single-molecule studies p
12 es age, nanodomains reposition, facilitating fused-in-sarcoma fibrilization at the condensate surface
13 complexity domain of the RNA-binding protein Fused in Sarcoma (FUS LC) is structurally disordered and
14 on between two nuclear RNA binding proteins: fused in sarcoma (FUS) and splicing factor, proline- and
15 Mutations in RNA-binding proteins, including fused in sarcoma (FUS) and TAR DNA-binding protein 43 (T
16 le plaques, tau neurofibrillary tangles, and fused in sarcoma (FUS) and TAR DNA-binding protein 43 (T
17                                              Fused in sarcoma (FUS) and TAR DNA-binding protein 43 (T
18 ations in the RNA- and DNA-binding proteins, fused in sarcoma (FUS) and transactive response DNA-bind
19 AR DNA-binding protein of 43 kDa (TDP-43) or Fused in sarcoma (FUS) are a hallmark of amyotrophic lat
20                  TAR DNA binding protein and fused in sarcoma (FUS) are both RNA processing proteins
21         Mutations in the RNA binding protein Fused in sarcoma (FUS) are estimated to account for 5-10
22 inclusions of aggregated RNA-binding protein fused in sarcoma (FUS) are hallmarks of ALS and frontote
23  TAR DNA-binding protein 43 kDa (TDP-43) and fused in sarcoma (FUS) are RNA-binding proteins that for
24                 Proteomics analysis uncovers fused in sarcoma (FUS) as a downstream effector of PRMT5
25 ssemblies of multivalent RNA-binding protein fused in sarcoma (FUS) can exist in the functional liqui
26                      The RNA-binding protein fused in sarcoma (FUS) can form pathogenic inclusions in
27                       Pathogenic variants of fused in sarcoma (FUS) cause amyotrophic lateral scleros
28               Mutations in the gene encoding Fused in Sarcoma (FUS) cause amyotrophic lateral scleros
29         Mutations in the RNA-binding protein Fused in Sarcoma (FUS) cause early-onset amyotrophic lat
30      Ubiquitin-positive inclusion containing Fused in Sarcoma (FUS) defines a new subtype of frontote
31                                              Fused in sarcoma (FUS) encodes an RNA-binding protein wi
32                      The RNA-binding protein fused in sarcoma (FUS) forms physiological granules and
33 ts, representing a range of mutations in the fused in sarcoma (FUS) gene and ages of onset.
34                             Mutations in the fused in sarcoma (FUS) gene can cause both juvenile and
35                                 Mutations in Fused in sarcoma (FUS) gene cause a subset of familial a
36                             Dysregulation of Fused in Sarcoma (FUS) gene expression is associated wit
37            Liquid-liquid phase separation of Fused in sarcoma (FUS) has been extensively studied due
38 ied a missense mutation in the gene encoding fused in sarcoma (FUS) in a British kindred, linked to A
39  study establishes the physiological role of Fused in Sarcoma (FUS) in mitochondrial DNA (mtDNA) repa
40                                 Pathological fused in sarcoma (FUS) inclusions are found in 10% of pa
41                                              Fused in sarcoma (FUS) is a DNA/RNA binding protein and
42                         Aberrantly expressed fused in sarcoma (FUS) is a hallmark of FUS-related amyo
43                                              FUsed in Sarcoma (FUS) is a multifunctional RNA binding
44                                              Fused in Sarcoma (FUS) is a nuclear RNA/DNA binding prot
45                                              Fused in sarcoma (FUS) is a predominantly nuclear RNA-bi
46                                              Fused in Sarcoma (FUS) is a ubiquitously expressed prote
47                                              Fused in sarcoma (FUS) is a ubiquitously expressed RNA-b
48                                              Fused in sarcoma (FUS) is an abundant RNA-binding protei
49                                              Fused in sarcoma (FUS) is an RNA-binding protein involve
50                                              Fused in sarcoma (FUS) is an RNA-binding protein that is
51 osphorylation of the RNA-DNA binding protein fused in sarcoma (FUS) is higher in Itgalpha1-null cells
52                                 Mutations in fused in sarcoma (FUS) lead to amyotrophic lateral scler
53 ocalization of the RNA-binding protein (RBP) fused in sarcoma (FUS) occur in variants of amyotrophic
54 ed in vitro that the DNA/RNA-binding protein fused in sarcoma (FUS) promotes fibrotic responses by tr
55                                              Fused in sarcoma (FUS) protein, linked to a number of ne
56  an intrinsically disordered region from the fused in sarcoma (FUS) protein, or by selecting the appr
57 lasmic inclusions of the RNA-binding protein fused in sarcoma (FUS) represent one type of membraneles
58 in 1 (CAPRIN1) suppresses aggregation of the Fused in Sarcoma (FUS) RNA Recognition Motif (RRM) clien
59 bling fibrils formed by the LC domain of the fused in sarcoma (FUS) RNA-binding protein.
60 ng the amino acid composition of the protein fused in sarcoma (FUS) to enhance glycosylation.
61                                  The protein Fused in Sarcoma (FUS) undergoes LLPS and mutations in F
62                                              Fused in sarcoma (FUS), a DNA/RNA-binding protein, is a
63 EMENT In the present study, we reported that fused in sarcoma (FUS), a DNA/RNA-binding protein, is up
64                                              Fused in sarcoma (FUS), a multifunctional deoxyribonucle
65  phase separation of the RNA-binding protein Fused in Sarcoma (FUS), although potency varies dependin
66 ALS, we expressed either wild-type or mutant Fused in Sarcoma (FUS), an RNA binding protein that is o
67 ulation of cytoplasmic inclusions containing fused in sarcoma (FUS), an RNA/DNA-binding protein, is a
68 sp104-RYD, which suppresses alpha-synuclein, fused in sarcoma (FUS), and TDP-43 toxicity.
69 ly of atypical RNA-binding proteins includes Fused in sarcoma (FUS), Ewing's sarcoma (EWS) and the TA
70 mplexity (LC) domains of the products of the fused in sarcoma (FUS), Ewings sarcoma (EWS), and TAF15
71 intrinsically disordered RGG/RG domains from Fused in Sarcoma (FUS), FMRP and hnRNPU.
72 c mislocalization of the RNA binding protein fused in sarcoma (FUS), in an unaggregated state, may oc
73 -binding proteins (RBPs), such as TDP-43 and fused in sarcoma (FUS), that through low-complexity, pri
74 Here, we demonstrate that the proto-oncogene fused in sarcoma (FUS), the chromatin remodeling ATPase
75 1), TAR DNA-binding protein 43 (TDP-43), and fused in sarcoma (FUS), we demonstrate selective degener
76 nstant nucleotide/protein ratio, the protein fused in sarcoma (FUS), which can phase separate on its
77 ics inside condensates formed by the protein fused in sarcoma (FUS).
78 to months, droplet maturation of the protein fused in sarcoma (FUS).
79 with ALS encodes the DNA/RNA-binding protein Fused in Sarcoma (FUS).
80 AR DNA-binding protein-43 (TDP-43), tau, and fused in sarcoma (FUS).
81 g protein 43 (TDP-43) or RNA-binding protein fused in sarcoma (FUS).
82 TD), including in ALS caused by mutations in Fused in Sarcoma (FUS).
83 idely believed to be composed of the protein fused in sarcoma (FUS, also known as translocated in lip
84 ng protein (TARDBP, also known as TDP43) and fused in sarcoma (FUS, also known as translocated in lip
85                 The RNA/DNA-binding proteins fused in sarcoma (FUS; also known as TLS) and TAR DNA bi
86 tudy how the prototypical prion-like protein Fused-in-Sarcoma (FUS) condenses with individual molecul
87                                              Fused-In-Sarcoma (FUS) is a candidate gene for neurologi
88 abundant factors associated with the protein fused-in-sarcoma (FUS), which is mutated to cause the ne
89 rs929867 (P = 6.21 x 10(-9)), is in the gene fused-in-sarcoma (FUS), with 4 other SNPs mapping to int
90 the low-complexity domain of the disordered 'fused in sarcoma' (FUS) protein at the air/water interfa
91                   Recently, mutations in the fused in sarcoma gene have been shown to cause familial
92 (FTD)-linked RNA-binding protein called FUS (fused in sarcoma) has been implicated in several aspects
93 anism in NEFL (neurofilament light) and FUS (fused in sarcoma), in which mutations are known to cause
94                             The protein FUS (FUSed in sarcoma) is a metazoan RNA-binding protein that
95 teractions between lipids and the disordered fused in sarcoma low-complexity (FUS LC) domain strongly
96                                           No fused in sarcoma mutations were found in any cases.
97 temporal atrophy (corticobasal degeneration, fused-in-sarcoma pathology).
98 nsactive response DNA binding protein 43 and fused-in-sarcoma pathology, cases of frontotemporal deme
99 42 (44%) had tau pathology and five (5%) had fused-in-sarcoma pathology.
100  or skein-like cytoplasmic inclusions in all fused in sarcoma-positive cases in which brainstem and s
101                          The co-existence of fused in sarcoma-positive inclusions in both motor neuro
102                                              Fused in sarcoma-positive neuronal cytoplasmic and intra
103             The distribution and severity of fused in sarcoma-positive neuronal cytoplasmic inclusion
104                                     Cortical fused in sarcoma-positive neuronal cytoplasmic inclusion
105 e familial amyotrophic lateral sclerosis and fused in sarcoma-positive neuronal inclusions have subse
106  overlap and also significant differences in fused in sarcoma-positive pathology between the two subg
107 -nuclear localization signal (PY-NLS) of the Fused in Sarcoma protein (FUS) cause amyotrophic lateral
108 to the low complexity sequence domain of the fused in sarcoma protein, which drives the assembly of R
109 ures is a characteristic finding in sporadic fused in sarcoma proteinopathies, indicating a multisyst
110 s well as genetic and biochemical data in 14 fused in sarcoma proteinopathy cases.
111 , synucleinopathies, TDP-43 proteinopathies, fused in sarcoma proteinopathy, prion disease (Creutzfel
112 ative for the TAR DNA binding protein 43 and fused in sarcoma proteins, mimicking the inclusions obse
113 degenerative diseases, including mutant FUS (Fused in sarcoma), SOD1 (superoxide dismutase 1), TDP43
114                     Biochemically, two major fused in sarcoma species were found and shown to be more
115  of condensates of fluorescently-tagged FUS (Fused in Sarcoma) that is associated with the formation
116 nding protein translocated in liposarcoma or fused in sarcoma (TLS/FUS or FUS).
117 ndc3b interacts with the RNA binding protein Fused in Sarcoma to regulate VEGF expression and signali
118 DR derived from the RNA granule protein FUS (fused in sarcoma) to a multivalent poly-Src homology 3 (
119                                              Fused in sarcoma/translated in liposarcoma (FUS/TLS) and
120           We report here 13 mutations in the fused in sarcoma/translated in liposarcoma (FUS/TLS) gen
121 TAR DNA-binding domain protein) and FUS/TLS (fused in sarcoma/translated in liposarcoma) cause a subs
122                                 Mutations in Fused in Sarcoma/Translocated in Liposarcoma (FUS) cause
123 rovide evidence that the RNA-binding protein fused in sarcoma/translocated in liposarcoma (FUS) is a
124 ding protein 43 (TDP-43) and, most robustly, fused in sarcoma/translocated in liposarcoma (FUS/TLS or
125 ve response DNA-binding protein (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS) a
126 tranuclear inclusions composed of TDP-43 and fused in sarcoma/translocated in liposarcoma (FUS/TLS),
127                                     FUS/TLS (fused in sarcoma/translocated in liposarcoma) and TDP-43
128 ociate with the RNA-binding protein Fus/TLS (fused in sarcoma/translocated in liposarcoma).
129 of the atypical RNA-binding protein fus/TLS (fused in sarcoma/translocated in sarcoma) during early f
130 oteins involved in RNA processing, including fused-in-sarcoma/translocated-in-sarcoma (FUS/TLS).
131 with a molecular mass of 43 KDa (TDP-43) and fused in sarcoma/translocation in liposarcoma (FUS/TLS),
132  models of familial ALS expressing the human fused in sarcoma variant R521G (hFUSR521G), along with p
133 ar inclusions and neurites were recorded and fused in sarcoma was biochemically analysed in both subg

 
Page Top